Previously, Alserihi et al. (2021) developed EGCG‐based folic acid NPs to bind FOLR1 receptors and prostate‐specific membrane antigen (PSMA+) in a PC model and reported the anticancer potential of EGCG‐FA‐NPs. Here, FOLH1 is linked to pachyonychia congenita.